BeOne Medicines Ltd. Class A
688235.SS
Price:
$274.3
Market Cap:
$40.77B
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small mole...[Read more]
Industry
Biotechnology
IPO Date
2021-12-15
Stock Exchange
SHH
Ticker
688235.SS
PE Ratio
[1.02K]
ROE
[-5.64%]
Current Ratio
[1.95]
Dividend Yield
[0%]
Enterprise Value
[39.04B]
Dividend History
The ROE as of December 2025 (TTM) for BeOne Medicines Ltd. Class A (688235.SS) is -5.64%
According to BeOne Medicines Ltd. Class A’s latest financial reports and current stock price. The company's current ROE is -5.64%. This represents a change of 267.95% compared to the average of -1.53% of the last 4 quarters.
BeOne Medicines Ltd. Class A (688235.SS) Historical ROE (quarterly & annually)
How has 688235.SS ROE performed in the past?
The mean historical ROE of BeOne Medicines Ltd. Class A over the last ten years is -28.20%. The current -5.64% ROE has changed -79.99% with respect to the historical average. Over the past ten years (40 quarters), 688235.SS's ROE was at its highest in in the December 2015 quarter at 26.78%. The ROE was at its lowest in in the December 2019 quarter at -39.66%.
Average
-28.20%
Median
-29.35%
Minimum
-96.96%
Maximum
56.11%
BeOne Medicines Ltd. Class A (688235.SS) ROE by Quarter and Year
Discovering the peaks and valleys of BeOne Medicines Ltd. Class A ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 182.36%
Maximum Annual ROE = 56.11%
Minimum Annual Increase = -179.11%
Minimum Annual ROE = -96.96%
| Year | ROE | Change |
|---|---|---|
| 2024 | -19.35% | -22.37% |
| 2023 | -24.93% | -45.47% |
| 2022 | -45.71% | 95.77% |
| 2021 | -23.35% | -44.40% |
| 2020 | -42.00% | -56.69% |
| 2019 | -96.96% | 152.37% |
| 2018 | -38.42% | 182.36% |
| 2017 | -13.61% | -59.72% |
| 2016 | -33.78% | -160.20% |
| 2015 | 56.11% | -179.11% |
BeOne Medicines Ltd. Class A (688235.SS) Average ROE
How has 688235.SS ROE performed in the past?
The current ROE of BeOne Medicines Ltd. Class A (688235.SS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-30.00%
5-year avg
-31.07%
10-year avg
-28.20%
BeOne Medicines Ltd. Class A (688235.SS) ROE vs. Peers
How is 688235.SS’s ROE compared to its peers?
BeOne Medicines Ltd. Class A’s ROE is less than WuXi AppTec Co., Ltd. (23.34%), less than Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (22.52%), greater than Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (-2.74%), greater than Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (-19.53%), less than Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (15.25%), greater than RemeGen Co Ltd (-44.94%), greater than Shanghai Junshi Biosciences Co., Ltd. (-15.79%), greater than Nanjing Vazyme Biotech Co., Ltd. (-0.76%), greater than Suzhou Zelgen Biopharmaceuticals Co., Ltd. (-11.10%), less than Sinocelltech Group Limited (430.69%),
| Company | ROE | Market cap |
|---|---|---|
| 23.34% | $225.59B | |
| 22.52% | $241.85B | |
| -2.74% | $59.31B | |
| -19.53% | $59.05B | |
| 15.25% | $36.96B | |
| -44.94% | $43.39B | |
| -15.79% | $34.58B | |
| -0.76% | $7.91B | |
| -11.10% | $26.84B | |
| 430.69% | $19.71B |
Build a custom stock screener for BeOne Medicines Ltd. Class A (688235.SS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BeOne Medicines Ltd. Class A using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
BeOne Medicines Ltd. Class A (688235.SS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like BeOne Medicines Ltd. Class A or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is BeOne Medicines Ltd. Class A's ROE?
How is the ROE calculated for BeOne Medicines Ltd. Class A (688235.SS)?
What is the highest ROE for BeOne Medicines Ltd. Class A (688235.SS)?
What is the 3-year average ROE for BeOne Medicines Ltd. Class A (688235.SS)?
What is the 5-year average ROE for BeOne Medicines Ltd. Class A (688235.SS)?
How does the current ROE for BeOne Medicines Ltd. Class A (688235.SS) compare to its historical average?